BioCryst Pharmaceuticals, Inc.

NASDAQ:BCRX

Biotechnology

Healthcare
$7.30 +1.02%

+$0.09 today

Market cap
$1.88B
Beta
0.56
P/E (TTM)
-4.8
EPS (TTM)
-$1.89
52W Low $6.00High $10.32

Volume 2.95M

Average 4.85M

BCRX Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

BioCryst Pharmaceuticals, Inc.NASDAQ: BCRX

Retained Earnings · Q2 FY2026 · quarter ended Jun 2026

Retained earnings remains negative

Q2 FY2026 retained earnings was -$2.15B, compared with -$1.76B a year earlier.

Context

  • Retained earnings amounted to 385.3% of total assets at the end of Q2 FY2026, down 0.7 pp from a year earlier.
  • Retained earnings grew in size in 2 of the last 3 fiscal years.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -21.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$2.15B+3.5% QoQ
Last fiscal yearDec 2025
-$1.51B+14.9% YoY
Year agoJun 2025
-$1.76B-21.8% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-21.8%——
1 year+14.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(1.51B) USD
Year-over-year change
+14.9%

Retained Earnings vs competitors

How BCRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -21.8% is the highest of 4, against a peer median of -42.5%.
  • Retained earnings amounts to 385.3% of total assets for BCRX, versus a peer median of 212.7%.
BCRX Competitors
Retained Earnings for BCRX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AVIRAtea Pharmaceuticals, Inc.Mar 2026-$568.01M USD-42.5%—212.7%
PHVSPharvaris N.V.Sep 2026-€716.58M EUR-34.6%—242.9%
VIRVir Biotechnology, Inc.Mar 2026-$1.32B USD-50.3%—129.0%
BCRXBioCryst Pharmaceuticals, Inc.Jun 2026-$2.15B USD-21.8%—385.3%
Peer median (excluding BCRX) —-42.5%—212.7%

Competitors are the stored peer set for BCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents504.39M304.77M110.64M104.92M89.74M
Short-term Investments3.21M119.54M278.34M216.14M185.01M
Net Receivables29.41M50.6M56.95M79.07M106.82M
Inventory15.79M27.53M28.68M8.09M5.4M
Other Current Assets3.35M14.06M21.35M13.75M17.38M
Total Current Assets566.14M516.5M495.97M421.97M404.35M
Property, Plant & Equipment (Net)15.19M8.62M20.91M19.79M18.99M
Goodwill00000
Intangible Assets00000
Long-term Investments6.83M18.08M021.72M61.16M
Tax Assets00000
Other Non-current Assets06.81M80K26.94M29.66M
Total Non-current Assets22.02M33.5M20.99M68.45M109.81M
Total Assets588.15M550M516.96M490.42M514.16M
Account Payables27.81M14.36M20.89M11.64M15.83M
Short-term Debt00035.45M0
Tax Payables2.62M410K000
Deferred Revenue1.42M1.22M000
Other Current Liabilities52M36.46M86.59M64.66M129.69M
Total Current Liabilities103.72M105.51M149.99M160.38M196.07M
Long-term Debt585.46M733.28M811.27M795.92M427.23M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities591.42M739.08M822.5M805.97M437.25M
Total Liabilities695.14M844.6M972.49M966.35M633.31M
Common Stock1.84M1.88M2.06M2.09M2.13M
Retained Earnings(1.21B)(1.45B)(1.68B)(1.77B)(1.51B)
Accumulated OCI177K26K1.34M921K38K
Other Stockholders Equity00000
Minority Interest00000
Total Equity(106.99M)(294.6M)(455.53M)(475.93M)(119.15M)
Total Debt593.24M741.45M825.15M841.42M438.87M
Net Debt88.85M436.69M714.51M736.5M349.14M

BioCryst Pharmaceuticals, Inc.

NASDAQ:BCRX

Intrinsic Alpha fair value

Locked

Current Price

$7.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.